Brief: Revance Provides Financial Outlook

Revance Therapeutics

08/01/2024 18:13

Jan 8 (Reuters) - Revance Therapeutics Inc  RVNC.O :
    * REVANCE PROVIDES CORPORATE UPDATE, PRELIMINARY FOURTH
QUARTER
AND FULL YEAR 2023 FINANCIAL RESULTS, AND FINANCIAL OUTLOOK
    * REVANCE THERAPEUTICS INC: PROVIDES 2024 PRODUCT REVENUE
GUIDANCE
OF AT LEAST $280 MILLION
    * REVANCE THERAPEUTICS INC: 2024 GAAP AND NON-GAAP OPERATING
EXPENSE GUIDANCE EXPECTED TO BE BELOW 2023 LEVELS
    * REVANCE THERAPEUTICS INC: EXPECTS TO ACHIEVE POSITIVE
ADJUSTED
EBITDA IN 2025
    * REVANCE THERAPEUTICS:PRELIMINARY UNAUDITED Q4 & FULL YEAR
2023
PRODUCT REVENUE OF BETWEEN $58 MILLION AND $59 MILLION AND $212
MILLION AND $213 MILLION RESPECTIVELY

Source text for Eikon:  ID:nBw2r7rx8a 
Further company coverage:  RVNC.O 

 ((Reuters.Briefs@thomsonreuters.com;))